Literature DB >> 32812017

Single-cell DNA amplicon sequencing reveals clonal heterogeneity and evolution in T-cell acute lymphoblastic leukemia.

Llucia Albertí-Servera1,2,3, Sofie Demeyer1,2,3, Inge Govaerts1,2,3, Toon Swings4, Jolien De Bie5, Olga Gielen1,2,3, Marco Brociner1,2,6, Lucienne Michaux1, Johan Maertens3,7,8, Anne Uyttebroeck3,9,10, Kim De Keersmaecker3,10, Nancy Boeckx5,10, Heidi Segers3,9,10, Jan Cools1,2,3.   

Abstract

T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive leukemia that is most frequent in children and is characterized by the presence of few chromosomal rearrangements and 10 to 20 somatic mutations in protein-coding regions at diagnosis. The majority of T-ALL cases harbor activating mutations in NOTCH1 together with mutations in genes implicated in kinase signaling, transcriptional regulation, or protein translation. To obtain more insight in the level of clonal heterogeneity at diagnosis and during treatment, we used single-cell targeted DNA sequencing with the Tapestri platform. We designed a custom ALL panel and obtained accurate single-nucleotide variant and small insertion-deletion mutation calling for 305 amplicons covering 110 genes in about 4400 cells per sample and time point. A total of 108 188 cells were analyzed for 25 samples of 8 T-ALL patients. We typically observed a major clone at diagnosis (>35% of the cells) accompanied by several minor clones of which some were less than 1% of the total number of cells. Four patients had >2 NOTCH1 mutations, some of which present in minor clones, indicating a strong pressure to acquire NOTCH1 mutations in developing T-ALL cells. By analyzing longitudinal samples, we detected the presence and clonal nature of residual leukemic cells and clones with a minor presence at diagnosis that evolved to clinically relevant major clones at later disease stages. Therefore, single-cell DNA amplicon sequencing is a sensitive assay to detect clonal architecture and evolution in T-ALL.
© 2021 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 32812017      PMCID: PMC7885827          DOI: 10.1182/blood.2020006996

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  31 in total

1.  Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia.

Authors:  Andrew P Weng; Adolfo A Ferrando; Woojoong Lee; John P Morris; Lewis B Silverman; Cheryll Sanchez-Irizarry; Stephen C Blacklow; A Thomas Look; Jon C Aster
Journal:  Science       Date:  2004-10-08       Impact factor: 47.728

2.  Droplet barcoding for single-cell transcriptomics applied to embryonic stem cells.

Authors:  Allon M Klein; Linas Mazutis; Ilke Akartuna; Naren Tallapragada; Adrian Veres; Victor Li; Leonid Peshkin; David A Weitz; Marc W Kirschner
Journal:  Cell       Date:  2015-05-21       Impact factor: 41.582

3.  Highly Parallel Genome-wide Expression Profiling of Individual Cells Using Nanoliter Droplets.

Authors:  Evan Z Macosko; Anindita Basu; Rahul Satija; James Nemesh; Karthik Shekhar; Melissa Goldman; Itay Tirosh; Allison R Bialas; Nolan Kamitaki; Emily M Martersteck; John J Trombetta; David A Weitz; Joshua R Sanes; Alex K Shalek; Aviv Regev; Steven A McCarroll
Journal:  Cell       Date:  2015-05-21       Impact factor: 41.582

4.  Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia.

Authors:  Irene Homminga; Rob Pieters; Anton W Langerak; Johan J de Rooi; Andrew Stubbs; Monique Verstegen; Maartje Vuerhard; Jessica Buijs-Gladdines; Clarissa Kooi; Petra Klous; Pieter van Vlierberghe; Adolfo A Ferrando; Jean Michel Cayuela; Brenda Verhaaf; H Berna Beverloo; Martin Horstmann; Valerie de Haas; Anna-Sophia Wiekmeijer; Karin Pike-Overzet; Frank J T Staal; Wouter de Laat; Jean Soulier; Francois Sigaux; Jules P P Meijerink
Journal:  Cancer Cell       Date:  2011-04-12       Impact factor: 31.743

5.  Single-cell sequencing data reveal widespread recurrence and loss of mutational hits in the life histories of tumors.

Authors:  Jack Kuipers; Katharina Jahn; Benjamin J Raphael; Niko Beerenwinkel
Journal:  Genome Res       Date:  2017-10-13       Impact factor: 9.043

6.  Impact of PTEN abnormalities on outcome in pediatric patients with T-cell acute lymphoblastic leukemia treated on the MRC UKALL2003 trial.

Authors:  S Jenkinson; A A Kirkwood; N Goulden; A Vora; D C Linch; R E Gale
Journal:  Leukemia       Date:  2015-07-29       Impact factor: 11.528

7.  Defining the molecular basis of oncogenic cooperation between TAL1 expression and Pten deletion in T-ALL using a novel pro-T-cell model system.

Authors:  S Bornschein; S Demeyer; R Stirparo; O Gielen; C Vicente; E Geerdens; B Ghesquière; S Aerts; J Cools; C E de Bock
Journal:  Leukemia       Date:  2017-11-20       Impact factor: 11.528

8.  The subclonal complexity of STIL-TAL1+ T-cell acute lymphoblastic leukaemia.

Authors:  Caroline L Furness; Marcela B Mansur; Victoria J Weston; Luca Ermini; Frederik W van Delft; Sarah Jenkinson; Rosemary Gale; Christine J Harrison; Maria S Pombo-de-Oliveira; Marta Sanchez-Martin; Adolfo A Ferrando; Pamela Kearns; Ian Titley; Anthony M Ford; Nicola E Potter; Mel Greaves
Journal:  Leukemia       Date:  2018-03-20       Impact factor: 11.528

9.  Cooperative Enhancer Activation by TLX1 and STAT5 Drives Development of NUP214-ABL1/TLX1-Positive T Cell Acute Lymphoblastic Leukemia.

Authors:  Marlies Vanden Bempt; Sofie Demeyer; Michaël Broux; Jolien De Bie; Simon Bornschein; Nicole Mentens; Roel Vandepoel; Ellen Geerdens; Enrico Radaelli; Beat C Bornhauser; Andreas E Kulozik; Jules P Meijerink; Jean-Pierre Bourquin; Charles E de Bock; Jan Cools
Journal:  Cancer Cell       Date:  2018-08-13       Impact factor: 31.743

10.  JAK/STAT Pathway Mutations in T-ALL, Including the STAT5B N642H Mutation, are Sensitive to JAK1/JAK3 Inhibitors.

Authors:  Inge Govaerts; Kris Jacobs; Roel Vandepoel; Jan Cools
Journal:  Hemasphere       Date:  2019-10-22
View more
  11 in total

1.  The genomic landscape of pediatric acute lymphoblastic leukemia.

Authors:  Samuel W Brady; Kathryn G Roberts; Zhaohui Gu; Lei Shi; Stanley Pounds; Deqing Pei; Cheng Cheng; Yunfeng Dai; Meenakshi Devidas; Chunxu Qu; Ashley N Hill; Debbie Payne-Turner; Xiaotu Ma; Ilaria Iacobucci; Pradyuamna Baviskar; Lei Wei; Sasi Arunachalam; Kohei Hagiwara; Yanling Liu; Diane A Flasch; Yu Liu; Matthew Parker; Xiaolong Chen; Abdelrahman H Elsayed; Omkar Pathak; Yongjin Li; Yiping Fan; J Robert Michael; Michael Rusch; Mark R Wilkinson; Scott Foy; Dale J Hedges; Scott Newman; Xin Zhou; Jian Wang; Colleen Reilly; Edgar Sioson; Stephen V Rice; Victor Pastor Loyola; Gang Wu; Evadnie Rampersaud; Shalini C Reshmi; Julie Gastier-Foster; Jaime M Guidry Auvil; Patee Gesuwan; Malcolm A Smith; Naomi Winick; Andrew J Carroll; Nyla A Heerema; Richard C Harvey; Cheryl L Willman; Eric Larsen; Elizabeth A Raetz; Michael J Borowitz; Brent L Wood; William L Carroll; Patrick A Zweidler-McKay; Karen R Rabin; Leonard A Mattano; Kelly W Maloney; Stuart S Winter; Michael J Burke; Wanda Salzer; Kimberly P Dunsmore; Anne L Angiolillo; Kristine R Crews; James R Downing; Sima Jeha; Ching-Hon Pui; William E Evans; Jun J Yang; Mary V Relling; Daniela S Gerhard; Mignon L Loh; Stephen P Hunger; Jinghui Zhang; Charles G Mullighan
Journal:  Nat Genet       Date:  2022-09-01       Impact factor: 41.307

Review 2.  The Promise of Single-cell Technology in Providing New Insights Into the Molecular Heterogeneity and Management of Acute Lymphoblastic Leukemia.

Authors:  Holly C L Pearson; Kooper V Hunt; Toby N Trahair; Richard B Lock; Heather J Lee; Charles E de Bock
Journal:  Hemasphere       Date:  2022-05-26

3.  Immunoglobulin Heavy Chain High-Throughput Sequencing in Pediatric B-Precursor Acute Lymphoblastic Leukemia: Is the Clonality of the Disease at Diagnosis Related to Its Prognosis?

Authors:  Gabriel Levy; Michal Kicinski; Jona Van der Straeten; Anne Uyttebroeck; Alina Ferster; Barbara De Moerloose; Marie-Francoise Dresse; Christophe Chantrain; Bénédicte Brichard; Marleen Bakkus
Journal:  Front Pediatr       Date:  2022-05-30       Impact factor: 3.569

Review 4.  Latest Contributions of Genomics to T-Cell Acute Lymphoblastic Leukemia (T-ALL).

Authors:  Eulàlia Genescà; Celia González-Gil
Journal:  Cancers (Basel)       Date:  2022-05-17       Impact factor: 6.575

Review 5.  Time to Move to the Single-Cell Level: Applications of Single-Cell Multi-Omics to Hematological Malignancies and Waldenström's Macroglobulinemia-A Particularly Heterogeneous Lymphoma.

Authors:  Ramón García-Sanz; Cristina Jiménez
Journal:  Cancers (Basel)       Date:  2021-03-26       Impact factor: 6.639

Review 6.  T-Cell Acute Lymphoblastic Leukemia: Biomarkers and Their Clinical Usefulness.

Authors:  Valentina Bardelli; Silvia Arniani; Valentina Pierini; Danika Di Giacomo; Tiziana Pierini; Paolo Gorello; Cristina Mecucci; Roberta La Starza
Journal:  Genes (Basel)       Date:  2021-07-23       Impact factor: 4.096

7.  Monitoring of Leukemia Clones in B-cell Acute Lymphoblastic Leukemia at Diagnosis and During Treatment by Single-cell DNA Amplicon Sequencing.

Authors:  Sarah Meyers; Llucia Alberti-Servera; Olga Gielen; Margot Erard; Toon Swings; Jolien De Bie; Lucienne Michaux; Barbara Dewaele; Nancy Boeckx; Anne Uyttebroeck; Kim De Keersmaecker; Johan Maertens; Heidi Segers; Jan Cools; Sofie Demeyer
Journal:  Hemasphere       Date:  2022-03-10

Review 8.  The Multi-Dimensional Biomarker Landscape in Cancer Immunotherapy.

Authors:  Jing Yi Lee; Bavani Kannan; Boon Yee Lim; Zhimei Li; Abner Herbert Lim; Jui Wan Loh; Tun Kiat Ko; Cedric Chuan-Young Ng; Jason Yongsheng Chan
Journal:  Int J Mol Sci       Date:  2022-07-16       Impact factor: 6.208

Review 9.  Natural Barcodes for Longitudinal Single Cell Tracking of Leukemic and Immune Cell Dynamics.

Authors:  Livius Penter; Satyen H Gohil; Catherine J Wu
Journal:  Front Immunol       Date:  2022-01-03       Impact factor: 8.786

Review 10.  Exploiting Single-Cell Tools in Gene and Cell Therapy.

Authors:  Daniel Bode; Alyssa H Cull; Juan A Rubio-Lara; David G Kent
Journal:  Front Immunol       Date:  2021-07-12       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.